Associated Papers
Novel JAK2 Exon 14 Mutations L611S or N622Y in cis with JAK2V617F Are Associated with Distinct Clinical Phenotype of Polycythemia Vera and Concurrent Eosinophilia.
Patel A et al.
Acta Haematologica, 2023
A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.
Gnanasambandan K et al.
Current Medicinal Chemistry, 2011
Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases.
Haan C et al.
Journal of Cellular and Molecular Medicine, 2010
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.
Tefferi A
Journal of Cellular and Molecular Medicine, 2009
Select a paper to view details